表紙
市場調查報告書

蛋白麩醯胺酸伽馬谷氨酰轉移酶2:開發中產品分析

Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 421233
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
蛋白麩醯胺酸伽馬谷氨酰轉移酶2:開發中產品分析 Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 38 Pages
簡介

本報告提供以蛋白麩醯胺酸伽馬谷氨酰轉移酶2為標的的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

蛋白麩醯胺酸伽馬谷氨酰轉移酶2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各分子類型

開發治療藥的企業

  • UCB SA
  • Zedira GmbH

藥物簡介

  • Angiocidin
  • 脂肪性肝炎TG2阻礙抗體
  • 纖維症用麩醯胺酸酶2阻礙抗體
  • ERW-1041E
  • ZED-1227
  • ZED-754

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1950TDB

Summary:

According to the recently published report 'Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2019'; Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Transglutaminase 2 (TG2) is a member of the transglutaminase family that catalyzes calcium-dependent posttranslational modification of proteins by inserting highly stable isopeptide bonds between polypeptide chains or by conjugating polyamines to proteins. TG2 also exhibits GTPase activity and can serve as a signal-transduction G protein.

The report 'Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Cardiovascular, Infectious Disease, Oncology and Respiratory which include indications Celiac Disease, Burkholderia Infections, Cardiovascular Disease, Cystic Fibrosis, Pseudomonas aeruginosa Infections and Renal Cell Carcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13)
  • The report reviews Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Overview
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Companies Involved in Therapeutics Development
    • Catabasis Pharmaceuticals Inc
    • GlaxoSmithKline Plc
    • Zedira GmbH
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Drug Profiles
    • CAT-5571 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DN-201782 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ERW-1041E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESTUS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZED-1227 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZED-754 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Dormant Products
  • Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or Tgase C or Tgase H or TGM2 or EC 2.3.2.13) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 26, 2017: Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
      • Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
      • Jun 02, 2017: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
      • May 02, 2017: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
      • Jan 05, 2017: Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
      • Nov 30, 2016: Zedira receives funding from the German Government for the development of transglutaminase inhibitor ZED-1227 for the treatment of diabetic nephropathy
      • Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-5571 at Investor Day
      • Oct 27, 2016: Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
      • Oct 20, 2016: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
      • Jul 01, 2016: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
      • Oct 20, 2015: Additional subsidy funding for clinical development of a celiac disease drug
      • Mar 02, 2015: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
      • Mar 19, 2009: Numerate Awarded Phase 1 NIH Grant To Support Design Of New Therapies For Celiac Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Zedira GmbH, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top